Business
Natera Announces Launch of ABCSG 61 ("TEODOR"), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer
AUSTIN, Texas, July 29, 2025--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of the TEODOR trial (Neoadjuvant TrEatment Optimization driven by ctDNA and endOcrine Responsiveness). TEODOR is a Phase II, multicenter, randomized controlled trial (RCT) that aims to replace chemotherapy with endocrine therapy prior to surgery for a subset of women with hormone receptor-positive (HR+), HER2-negative breast cancer, who are endocrine resp
About this update from Natera, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":200,"url":"https://media.zenfs.com/en/business-wire.com/3076a6fd5da4ac6d93b834b10dc7e3e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SE_LDN._Ocly09Sv.ZLIUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3076a6fd5da4ac6d93b834b10dc7e3e7","width":200,"height":200}},"lazy":false},{"type":"text","content":"Study utilizes Signatera to identify HR+, HER2-negative breast cancer patients for de-escalation of neoadjuvant chemotherapy","length":124,"tagName":"p","attribs":{}},{"type":"text","content":"AUSTIN, Texas, July 29, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of the TEODOR trial (Neoadjuvant TrEatment Optimization driven by ctDNA and endOcrine Responsiveness). TEODOR is a Phase II, multicenter, randomized controlled trial (RCT) that aims to replace chemotherapy with endocrine therapy prior to surgery for a subset of women with hormone receptor-positive (HR+), HER2-negative breast cancer, who are endocrine responsive and test negative with Signatera.","length":557,"tagName":"p"},{"type":"text","content":"Sponsored by the Austrian Breast & Colorectal Cancer Study Group (ABCSG), TEODOR expects to enroll approximately 250 patients across 15 sites in Austria. Previous studies have demonstrated that patients who test Signatera-negative at diagnosis and then receive chemotherapy have excellent outcomes, with risk of recurrence at less than 5%. In an effort to reduce pre-operative chemotherapy, which can carry significant side effects, this study is designed to evaluate the efficacy of endocrine therapy compared to chemotherapy in patients who are Signatera-negative.","length":570,"tagName":"p"},{"type":"text","content":"After a four-week course of endocrine therapy, patients who are Signatera-negative and show a favorable endocrine sensitivity as measured by the Ki-67 proliferation index will be randomized to receive either additional endocrine therapy or chemotherapy. The primary endpoint of the study is the rate of neoadjuvant therapy response, assessed via pathological complete response (pCR) and modified Preoperative Endocrine Prognostic In...